Connect Biopharma Holdings
CNTB
29 hedge funds and large institutions have $13M invested in Connect Biopharma Holdings in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more funds holding
Funds holding: 28 → 29 (+1)
3.62% less ownership
Funds ownership: 30.8% → 27.18% (-3.6%)
76% less capital invested
Capital invested by funds: $53.4M → $13M (-$40.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$959K |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$754K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$603K |
| 4 |
Citigroup
New York
|
+$551K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$368K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.36M |
| 2 |
RI
RTW Investments
New York
|
-$1.35M |
| 3 |
Janus Henderson Group
London,
|
-$1.3M |
| 4 |
BlackRock
New York
|
-$1.18M |
| 5 |
Barclays
London,
United Kingdom
|
-$947K |
CNTB Hedge Fund Activity: Q2 2022 in Review
29 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q2 2022, worth a combined $13M — down 76% from $53.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CNTB positions and 6 closed out — a net gain of 1 holder — while 9 added to existing stakes and 6 trimmed.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $959K. The largest seller was Fidelity Investments, cutting an estimated $3.36M.
- 29 institutional investors held Connect Biopharma Holdings (CNTB) as of Q2 2022, up from 28 in Q1 2022.
- Funds reported $13M of Connect Biopharma Holdings stock for Q2 2022, down 76% quarter-over-quarter.
- 7 funds opened new Connect Biopharma Holdings positions in Q2 2022 and 6 closed out, a net change of +1 holder.
- The largest Connect Biopharma Holdings buyer in Q2 2022 was UBS O'Connor, an estimated $959K added.
- The largest Connect Biopharma Holdings seller in Q2 2022 was Fidelity Investments, an estimated $3.36M sold.
Based on aggregated 13F filings for Q2 2022.